S'abonner

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study - 01/08/16

Doi : 10.1016/S1470-2045(16)30067-5 
Marissa C van Maaren, MSc a, Linda de Munck, MSc a, Geertruida H de Bock, ProfPhD b, Jan J Jobsen, PhD c, Thijs van Dalen, PhD d, Sabine C Linn, ProfPhD e, f, Philip Poortmans, ProfPhD g, , Luc J A Strobbe, PhD h, , Sabine Siesling, ProfPhD a, i,
a Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands 
b Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands 
c Department of Radiation Oncology, Medical Spectrum Twente, Enschede, Netherlands 
d Department of Surgery, Diakonessenhuis Utrecht, Utrecht, Netherlands 
e Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands 
f Department of Pathology, University Medical Centre Utrecht, Utrecht, Netherlands 
g Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, Netherlands 
h Department of Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands 
i Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands 

* Correspondence to: Prof S Siesling, Department of Research, Netherlands Comprehensive Cancer Organisation, 3501 DB, Utrecht, Netherlands Correspondence to: Prof S Siesling Department of Research Netherlands Comprehensive Cancer Organisation Utrecht DB 3501 Netherlands

Summary

Background

Investigators of registry-based studies report improved survival for breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer. As these studies did not present long-term overall and breast cancer-specific survival, the effect of breast-conserving surgery plus radiotherapy might be overestimated. In this study, we aimed to evaluate 10 year overall and breast cancer-specific survival after breast-conserving surgery plus radiotherapy compared with mastectomy in Dutch women with early breast cancer.

Methods

In this population-based study, we selected all women from the Netherlands Cancer Registry diagnosed with primary, invasive, stage T1–2, N0–1, M0 breast cancer between Jan 1, 2000, and Dec 31, 2004, given either breast-conserving surgery plus radiotherapy or mastectomy, irrespective of axillary staging or dissection or use of adjuvant systemic therapy. Primary outcomes were 10 year overall survival in the entire cohort and breast cancer-specific survival in a representative subcohort of patients diagnosed in 2003 with characteristics similar to the entire cohort. We estimated breast cancer-specific survival by calculating distant metastasis-free and relative survival for every tumour and nodal category. We did multivariable Cox proportional hazard analysis to estimate hazard ratios (HRs) for overall and distant metastasis-free survival. We estimated relative survival by calculating excess mortality ratios using life tables of the general population. We did multiple imputation to account for missing data.

Findings

Of the 37 207 patients included in this study, 21 734 (58%) received breast-conserving surgery plus radiotherapy and 15 473 (42%) received mastectomy. The 2003 representative subcohort consisted of 7552 (20%) patients, of whom 4647 (62%) received breast-conserving surgery plus radiotherapy and 2905 (38%) received mastectomy. For both unadjusted and adjusted analysis accounting for various confounding factors, breast-conserving surgery plus radiotherapy was significantly associated with improved 10 year overall survival in the whole cohort overall compared with mastectomy (HR 0·51 [95% CI 0·49–0·53]; p<0·0001; adjusted HR 0·81 [0·78–0·85]; p<0·0001), and this improvement remained significant for all subgroups of different T and N stages of breast cancer. After adjustment for confounding variables, breast-conserving surgery plus radiotherapy did not significantly improve 10 year distant metastasis-free survival in the 2003 cohort overall compared with mastectomy (adjusted HR 0·88 [0·77–1·01]; p=0·07), but did in the T1N0 subgroup (adjusted 0·74 [0·58–0·94]; p=0·014). Breast-conserving surgery plus radiotherapy did significantly improve 10 year relative survival in the 2003 cohort overall (adjusted 0·76 [0·64–0·91]; p=0·003) and in the T1N0 subgroup (adjusted 0·60 [0·42–0·85]; p=0·004) compared with mastectomy.

Interpretation

Adjusting for confounding variables, breast-conserving surgery plus radiotherapy showed improved 10 year overall and relative survival compared with mastectomy in early breast cancer, but 10 year distant metastasis-free survival was improved with breast-conserving surgery plus radiotherapy compared with mastectomy in the T1N0 subgroup only, indicating a possible role of confounding by severity. These results suggest that breast-conserving surgery plus radiotherapy is at least equivalent to mastectomy with respect to overall survival and may influence treatment decision making for patients with early breast cancer.

Funding

None.

Le texte complet de cet article est disponible en PDF.

Plan


© 2016  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 17 - N° 8

P. 1158-1170 - août 2016 Retour au numéro
Article précédent Article précédent
  • Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
  • Koichi Goto, Yuichiro Ohe, Taro Shibata, Takashi Seto, Toshiaki Takahashi, Kazuhiko Nakagawa, Hiroshi Tanaka, Koji Takeda, Makoto Nishio, Kiyoshi Mori, Miyako Satouchi, Toyoaki Hida, Naruo Yoshimura, Toshiyuki Kozuki, Fumio Imamura, Katsuyuki Kiura, Hiroaki Okamoto, Toshiyuki Sawa, Tomohide Tamura, JCOG0605 investigators
| Article suivant Article suivant
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
  • Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos, Meletios Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans E Johnsen, Evangelos Terpos, Anthony Reiman, Robert A Kyle, Pieter Sonneveld, Paul G Richardson, Philip McCarthy, Heinz Ludwig, Wenming Chen, Michele Cavo, Jean-Luc Harousseau, Suzanne Lentzsch, Jens Hillengass, Antonio Palumbo, Alberto Orfao, S Vincent Rajkumar, Jesus San Miguel, Herve Avet-Loiseau

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.